SOUTH SAN FRANCISCO, CA: Marks Second FDA Fast Track Designation for Evofosfamide, an Investigational Compound Currently in Phase 3 Clinical Trials
...
SAN FRANCISCO, CA: Reaffirms Full-Year 2015 Non-GAAP Collaboration Revenue and Operating Expense Guidance; First Quarter GAAP Collaboration Revenue $129.2 Million (+48% vs. Prior Year); First Quarter GAAP Net Loss $3.1 ...
NEEDHAM, MA: Showcase of Innovations, Best Practices and Outstanding Contributions to the Advancement of Life Science Research, Workflow and Data Sharing
...
Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.